Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1988 Aug;64(4):733–738.

Abnormal T-cell activation in chronic hepatitis B viral infection: a consequence of monocyte dysfunction?

K T Nouri-Aria 1, S Magrin 1, G J Alexander 1, M G Anderson 1, R Williams 1, A L Eddleston 1
PMCID: PMC1384999  PMID: 2971612

Abstract

The process of T-cell activation in chronic hepatitis B virus (HBV) carriers has been investigated by measurement of membrane expression of lymphocyte-activation markers in response to a variety of mitogenic stimuli in order to delineate further the abnormality of T-cell-mediated immunity present in such patients. A substantial proportion of unstimulated T cells from the peripheral blood of patients but not controls expressed HLA-DR; in contrast the IL-2 and transferrin receptors were rarely expressed spontaneously in either group and there was no difference in spontaneous lymphocyte transformation. After stimulation with monocyte-dependent T-cell mitogens, phytohaemagglutinin (PHA) or anti-T3, patients had significantly reduced expression of the IL-2 and transferrin receptors and of HLA-DR in association with impaired lymphocyte transformations compared to controls. In contrast, lymphocyte activation was normal in response to the monocyte-independent T-cell mitogen phorbol-myristate-acetate (PMA). These data confirm that the process of T-cell activation is abnormal in chronic HBV carriers but suggest that the T cell is intrinsically normal. In allogeneic co-cultures, monocytes from patients inhibited the transformation of normal and patients' lymphocytes in response to PHA, suggesting that defects of T-cell-mediated immunity in chronic HBV carriers may be a consequence of monocyte dysfunction.

Full text

PDF
733

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anastassakos C., Alexander G. J., Wolstencroft R. A., Avery J. A., Portmann B. C., Panayi G. S., Dumonde D. C., Eddleston A. L., Williams R. Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology. 1988 Apr;94(4):999–1005. doi: 10.1016/0016-5085(88)90559-8. [DOI] [PubMed] [Google Scholar]
  2. Anastassakos C., Alexander G. J., Wolstencroft R. A., Dumonde D. C., Eddleston A. L., Williams R. Failure of exogenous interleukin 1 and interleukin 2 to correct decreased lymphocyte transformation in chronic hepatitis B virus carriers. Clin Exp Immunol. 1987 Apr;68(1):15–22. [PMC free article] [PubMed] [Google Scholar]
  3. Barker L. F., Murray R. Aquisition of hepatitis-associated antigen. Clinical features in young adults. JAMA. 1971 Jun 21;216(12):1970–1976. [PubMed] [Google Scholar]
  4. Beasley R. P., Hwang L. Y., Stevens C. E., Lin C. C., Hsieh F. J., Wang K. Y., Sun T. S., Szmuness W. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983 Mar-Apr;3(2):135–141. doi: 10.1002/hep.1840030201. [DOI] [PubMed] [Google Scholar]
  5. Blumberg B. S., Sutnick A. I., London W. T. Australia antigen as a hepatitis virus. Variation in host response. Am J Med. 1970 Jan;48(1):1–8. doi: 10.1016/0002-9343(70)90093-8. [DOI] [PubMed] [Google Scholar]
  6. Chisari F. V., Castle K. L., Xavier C., Anderson D. S. Functional properties of lymphocyte subpopulations in hepatitis B virus infection. I. Suppressor cell control of T lymphocyte responsiveness. J Immunol. 1981 Jan;126(1):38–44. [PubMed] [Google Scholar]
  7. Colucci G., Colombo M., Del Ninno E., Paronetto F. In situ characterization by monoclonal antibodies of the mononuclear cell infiltrate in chronic active hepatitis. Gastroenterology. 1983 Nov;85(5):1138–1145. [PubMed] [Google Scholar]
  8. Davis L., Lipsky P. E. Signals involved in T cell activation. I. Phorbol esters enhance responsiveness but cannot replace intact accessory cells in the induction of mitogen-stimulated T cell proliferation. J Immunol. 1985 Nov;135(5):2946–2952. [PubMed] [Google Scholar]
  9. Davison F., Alexander G. J., Anastassakos C., Fagan E. A., Williams R. Leucocyte hepatitis B virus DNA in acute and chronic hepatitis B virus infection. J Med Virol. 1987 Aug;22(4):379–385. doi: 10.1002/jmv.1890220411. [DOI] [PubMed] [Google Scholar]
  10. Depper J. M., Leonard W. J., Krönke M., Noguchi P. D., Cunningham R. E., Waldmann T. A., Greene W. C. Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol. 1984 Dec;133(6):3054–3061. [PubMed] [Google Scholar]
  11. Fukui K., Kakumu S., Murakami H., Kuriki J., Yoshioka K., Sakamoto N. Increased peripheral blood Ia positive T cells and their effect on autologous mixed lymphocyte reaction in chronic active liver disease. Clin Exp Immunol. 1984 Oct;58(1):90–96. [PMC free article] [PubMed] [Google Scholar]
  12. Gerety R. J., Hoofnagle J. H., Markenson J. A., Barker L. F. Exposure to hepatitis B virus and development of the chronic HBAg carrier state in children. J Pediatr. 1974 May;84(5):661–665. doi: 10.1016/s0022-3476(74)80006-5. [DOI] [PubMed] [Google Scholar]
  13. Giustino V., Dudley F. J., Sherlock S. Thymus-dependent lymphocyte function in patients with hepatitis-associated antigen. Lancet. 1972 Oct 21;2(7782):850–853. doi: 10.1016/s0140-6736(72)92212-x. [DOI] [PubMed] [Google Scholar]
  14. Hanson R. G., Hoofnagle J. H., Minuk G. Y., Purcell R. H., Gerin J. L. Cell-mediated immunity to hepatitis B surface antigen in man. Clin Exp Immunol. 1984 Aug;57(2):257–264. [PMC free article] [PubMed] [Google Scholar]
  15. Hara T., Fu S. M., Hansen J. A. Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med. 1985 Jun 1;161(6):1513–1524. doi: 10.1084/jem.161.6.1513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hara T., Fu S. M. Human T cell activation. I. Monocyte-independent activation and proliferation induced by anti-T3 monoclonal antibodies in the presence of tumor promoter 12-o-tetradecanoyl phorbol-13 acetate. J Exp Med. 1985 Apr 1;161(4):641–656. doi: 10.1084/jem.161.4.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kato Y., Nakagawa H., Kobayashi K., Hattori N., Hatano K. Interferon production by peripheral lymphocytes in HBsAg-positive liver diseases. Hepatology. 1982 Nov-Dec;2(6):789–790. doi: 10.1002/hep.1840020607. [DOI] [PubMed] [Google Scholar]
  18. Mogensen C. E. The glomerular permeability determined by dextran clearance using Sephadex gel filtration. Scand J Clin Lab Invest. 1968;21(1):77–82. doi: 10.3109/00365516809076979. [DOI] [PubMed] [Google Scholar]
  19. Sagnelli E., Manzillo G., Maio G., Pasquale G., Felaco F. M., Filippini P., Izzo C. M., Piccinino F. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet. 1980 Aug 23;2(8191):395–397. doi: 10.1016/s0140-6736(80)90442-0. [DOI] [PubMed] [Google Scholar]
  20. Saxena S., Nouri-Aria K. T., Anderson M. G., Williams R., Eddleston A. L. In vitro alpha-interferon treatment of peripheral blood mononuclear cells improves interleukin-2 activity in HBV-related chronic liver disease. J Hepatol. 1985;1(4):385–393. doi: 10.1016/s0168-8278(85)80776-5. [DOI] [PubMed] [Google Scholar]
  21. Stoller A., Collmann R. D. Incidence of infective hepatitis followed by Down's syndrome nine months later. Lancet. 1965 Dec 11;2(7424):1221–1223. doi: 10.1016/s0140-6736(65)90642-2. [DOI] [PubMed] [Google Scholar]
  22. Viola L., Barrison I. G., Paradinas F., Coleman J. C., Murray-Lyon I. M. Cell-mediated immunity in HBeAg-positive homosexuals with chronic liver disease. Br J Vener Dis. 1982 Feb;58(1):59–61. doi: 10.1136/sti.58.1.59. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES